The mission of the Transgenic Animal Shared Facility (TASF) is to provide comprehensive support in the development of novel transgenic models for the study of human cancer diseases. The core accomplishes this mission by providing the technologies and capabilities to assure the integrity of the model, from design of the transgene through production of the model organism, including all husbandry methods to assure health and long-term preservation. The TASF is a vital component of the UAB Comprehensive Cancer Center, and its research enterprise. Genetically modified murine models continue to be the most tractable system to examine the role of an identified genetic variant associated with human disease, as well as creating much needed translational models for developing novel therapeutics. This shared facility provides unique services for model development and has a long track record of outstanding service. Twenty-two funded CCC investigators used the service to generate models, and have used them to conduct pre-clinical trials for treatments of cancers such as neurofibromatosis, to understand key mechanisms in breast cancer pathogenesis, and to understand the roles of mitochondrial inheritance in cancer. Although there are external commercial or academic alternatives for generating genetic models, they are often prohibitively costly, and there are none that supply the complete set of services provided by this facility in a convenient and timely manner.
Appropriate genetic models are critical for understanding the roles of specific genes in the genesis and progression of cancer. They are also necessary for creating translational models that allow for the development of novel therapeutics. Our ability to apply genetic technologies supports the work of CCC investigators in their efforts to understand and develop treatments for the myriad forms of cancer.
|Carson, Tiffany L; Hardy, Claudia M; Greene, Eva et al. (2014) Considerations for bio-specimen collection among black women residing in the rural Deep South participating in a cancer prevention study. J Community Genet 5:257-63|
|Fauci, Janelle M; Sabbatino, Francesco; Wang, Yangyang et al. (2014) Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96. Gynecol Oncol 132:203-10|
|Devine, D J; Rostas, J W; Metge, B J et al. (2014) Loss of N-Myc interactor promotes epithelial-mesenchymal transition by activation of TGF-*/SMAD signaling. Oncogene 33:2620-8|
|Kim, Hyunki; Rigell, Christopher J; Zhai, Guihua et al. (2014) Antagonistic effects of anti-EMMPRIN antibody when combined with chemotherapy against hypovascular pancreatic cancers. Mol Imaging Biol 16:85-94|
|Saini, Reshu; Hoyt, Kenneth (2014) Recent developments in dynamic contrast-enhanced ultrasound imaging of tumor angiogenesis. Imaging Med 6:41-52|
|Sonpavde, Guru; Willey, Christopher D; Sudarshan, Sunil (2014) Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma. Expert Opin Investig Drugs 23:305-15|
|Shim, Eun-Hee; Livi, Carolina B; Rakheja, Dinesh et al. (2014) L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer. Cancer Discov 4:1290-8|
|Gan, Yujun; Buckels, Ashiya; Liu, Ying et al. (2014) Human GH receptor-IGF-1 receptor interaction: implications for GH signaling. Mol Endocrinol 28:1841-54|
|Johnson, David H; Wilson, W William; DeLucas, Lawrence J (2014) Protein solubilization: a novel approach. J Chromatogr B Analyt Technol Biomed Life Sci 971:99-106|
|Ramos, Theresa N; Bullard, Daniel C; Barnum, Scott R (2014) ICAM-1: isoforms and phenotypes. J Immunol 192:4469-74|
Showing the most recent 10 out of 364 publications